Dynamics (NASDAQ:DYNS) announced in an 8-K filing this afternoon that its shareholders have voted to approve its combination with Gene Circuit company Senti Biosciences in a special meeting held earlier today.
Holders of 14,549,537 shares of Class A common stock elected to redeem their public shares resulting in 63.259% of Dynamic’s trust being removed. DYNS had previously secured a non-redemption agreement with a number of institutional investors including Morgan Stanley Investment Management Inc., T. Rowe Price Group, Inc., The Invus Group, LLC and ARK Investment Management LLC. Each of these investors agreed not to redeem their shares at the combination vote.
As background, Dynamics brought $230 million into the deal, which it supplemented with a $66.8 million PIPE at $10 per share. The PIPE drew investment from healthcare and technology investors, including 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global, Invus, LifeForce Capital, NEA, Parker Institute for Cancer Immunotherapy, T. Rowe Price Associates, and others.
The deal is expected to close tomorrow, June 8, and the combined company is expected to trade on the Nasdaq.
Dynamics initially announced the $276 million combination with Senti BioSciences on December 20, 2021. San Francisco-based Senti Bio uses its Gene Circuit platform to develop next-generation cell and gene therapies to enhance therapeutic effectiveness against diseases.
At the special meeting, the company’s stockholders also approved, among other items, the New Senti 2022 Equity Incentive Plan and the New Senti 2022 Employee Stock Purchase Plan.
ADVISORS
- J.P. Morgan is acting as lead capital markets advisor to Dynamics and co-placement agent for the PIPE.
- Morgan Stanley & Co. LLC is acting as financial advisor to Dynamics and co-placement agent to Dynamics for the PIPE.
- BofA Securities is acting as exclusive financial advisor to Senti Bio and as co-placement agent for the PIPE.
- Davis Polk & Wardwell LLP is serving as legal advisor to Dynamics.
- Goodwin Procter LLP is serving as legal advisor to Senti Bio
- Latham & Watkins LLP is serving as legal advisor to J.P. Morgan
- Morgan Stanley & Co. LLC and BofA Securities in their role as placement agents
Mobiv Acquisition Corp. (NASDAQ:MOBV) announced this afternoon that it has closed its combination with EV motorcycle-maker SRIVARU. Shareholders originally approved the deal at a special meeting held back on September 28, but at that time, the parties expected the transaction to take just a week to close. Redemptions whittled Mobiv’s IPO share pool of 10,005,000 down...
Achari Ventures I (NASDAQ:AVHI) has entered into a definitive agreement to combine with medtech firm Vaso Corporation at an equity value of $176 million, or 19.5x its 2022 adjusted EBITDA. Wuxi, China-based Vaso provides IT services and sales support to medical device manufacturers. The combined company is expected to trade on the Nasdaq under the...
EF Hutton Acquisition Corp. I (NASDAQ:EFHT) announced this morning that its shareholders have approved its business combination with E.C.D. Auto Design. At the meeting, there were 5,089,203 shares of common stock, representing approximately 76.82% of the issued and outstanding shares of common stock, present. In connection with the meeting, the company’s stockholders holding 3,470,945 shares,...
Legato Merger Corp. III (NYSE:LEGT) filed for a $175 million IPO yesterday afternoon, becoming the fourth SPAC to file this week. While the other three SPACs that filed their S-1s earlier this week intend to pursue targets in the financial services and biotech industries, Legato III, similar to the earlier Legato SPACs, will focus on...
At the SPAC of Dawn This week ends with an unusually busy earnings calendar as 172 US-listed companies report quarterly figures today. Among them is Exela Technologies (NASDSAQ:XELA), which completed a combination with Quinpario 2 in 2017. The billing software company has gone on to do another SPAC deal on November 29, this time spinning...